

## Supplementary Table

**Table 1S Characteristics of antiplatelet medication users stratified by CMB presence.**

Variables	Total (n = 64)	CMB present (n = 32)	CMB absent (n = 32)	P-value
Age, yrs	69.63 ± 8.56	70.88 ± 8.04	68.38 ± 9.00	0.246
Men	35 (54.69%)	23 (71.88%)	12 (37.50%)	0.006
History of smoke	15 (23.44%)	9 (28.13%)	6 (18.75%)	0.376
Alcohol consumption	29 (45.31%)	15 (46.88%)	14 (43.75%)	0.802
Medical history				
Hypertension	46 (71.88%)	23 (71.88%)	23 (71.88%)	0.999
Dyslipidemia	49 (76.56%)	22 (68.75%)	27 (84.38%)	0.140
Diabetes mellitus	16 (25.00%)	7 (21.88%)	9 (28.13%)	0.564
Atrial fibrillation	6 (9.38%)	4 (12.50%)	2 (6.25%)	0.672
History of medication				
Antihypertensive medication	44 (68.75%)	22 (68.75%)	22 (68.75%)	0.999
Lipid-lowering medication	46 (71.88%)	21 (65.63%)	25 (78.13%)	0.266
Oral hypoglycemic agents or insulin	12 (18.75%)	5 (15.63%)	7 (21.88%)	0.522
Physical examination				
Body mass index, kg/m <sup>2</sup>	24.67 ± 3.71	24.56 ± 3.56	24.77 ± 3.92	0.821
Systolic blood pressure, mmHg	131.18 ± 15.19	128.80 ± 14.68	133.56 ± 15.54	0.213
Diastolic blood pressure, mmHg	73.77 ± 8.81	73.30 ± 9.02	74.25 ± 8.72	0.669
Laboratory examination				
Fasting blood glucose, mmol/L	5.24 ± 1.09	5.17 ± 1.29	5.31 ± 0.85	0.619
Hemoglobin A1c, %	6.08 ± 0.79	6.17 ± 0.92	6.00 ± 0.64	0.409
Low-density lipoprotein cholesterol, mmol/L	2.49 ± 0.77	2.53 ± 0.63	2.45 ± 0.89	0.680
High-density lipoprotein cholesterol, mmol/L	1.46 ± 0.36	1.37 ± 0.35	1.56 ± 0.35	0.035
High-sensitivity C-reactive protein, mg/L	0.80 (0.60–2.25) <sup>*</sup>	0.80 (0.60–2.00) <sup>*</sup>	0.95 (0.50–2.65) <sup>*</sup>	0.989

Data are presented as means ± SD or n (%). <sup>\*</sup>Presented as median (interquartile range). CMB: cerebral microbleed.